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Abstract
Pharmacokinetic profile, tissue concentra-
tions and urine elimination of cephalothin in
cats under surgical conditions after a single
intravenous dose (30 mg/kg) were studied.
Initial plasma concentrations were high [Cp(0),
353.79±118.92 µg/mL], with fast and moder-
ately wide distribution [T½(d) 0.14±0.10 h]
[V(d(ss)) 0.19±0.03 L/kg] and rapid elimination
(ClB, 0.16±0.03 L/h.kg; T½, 1.07±0.23 h; MRT,
1.16±0.21 h). Thirty to 60 minutes after intra-
venous administration, cephalothin tissue
concentrations were in the range of 3.73 µg/g
(testicle tissue) to 25.63 µg/g (uterus).
Tissue/plasma concentrations rate was in a
range of 0.04 (testicle) to 0.21 (uterus).
Cephalothin urine elimination was 66.49% in
the first 6 hours after administration.
Cephalothin plasma concentrations remained
above a minimum inhibitory concentration
(MIC)≥1 µg/mL up to 5.5 hours in all the stud-
ied cats. However, for MIC≥8 µg/mL (MIC
breakpoint) this time is reduced to 2.5 hours.
This suggests that proper perioperative pro-
phylactic use of cephalothin in cats requires a
dose interval not longer than 2 hours. 
Introduction 
Cephalothin, along with cefazolin, is a mem-
ber of the parenteral first-generation
cephalosporins. It is active against many gram-
positive cocci, like Staphylococcus spp., includ-
ing beta-lactamase producing strains, and
Streptococcus spp (except Enterococcus). It is
also active against some gram-negative rods
like those of the Enterobacteriaceae family (E.
coli, Klebsiella, Proteus mirabilis) and
Pasteurella spp; and, it has some activity
against anaerobes.1,2 Minimum inhibitory con-
centration (MIC) breakpoint for bacteria iso-
lated from animals has been set in ≤8 µg/mL.3
Beta-lactams are classified as Type II antimi-
crobials which are characterized for a time-
dependent killing and minimal persistent
effects. The time they remain above the MIC
(T>MIC) is the PK/PD efficacy predictor that
best correlates with successful antibacterial
therapy. For cephalosporins, a T>MIC of 50% of
the dosing interval is considered suitable for
most gram-positive bacteria. However, for
gram-negative infections, bactericidal activity
is optimal with T>MIC of 60-70% of the dosing
interval.1 While, for neutropenic patients a
T>MIC of 90-100% is recommended.4
Cephalothin pharmacokinetics has been
studied in laboratory animals,5-7 dogs,7-10 and
horses.11 However, to the authors’ knowledge it
has not been studied in domestic cats. 
In most reported species, including human
beings, cephalothin is rapidly and widely dis-
tributed into pleural, pericardial, peritoneal,
and synovial fluids and most soft tissues.
However, as happens with most beta-lactam
antibiotics, its distribution is limited to the
extracellular fluid with a volume of distribu-
tion in the range of 0.2-0.3 L/kg.1,12 In humans,
cephalothin has a relatively high protein bind-
ing (around 50-60%),12 whereas, it is lower in
horses (18%) and dogs (20-46%).8,11,13
Cephalothin is partially metabolized to
desacetylcephalothin in the liver and, the par-
ent drug and the metabolite are excreted
through the kidneys by glomerular filtration
and tubular secretion.2,12 Extension of metabo-
lism varies with the species, being of 5-15% in
humans,14 and greater in rabbits, dogs and
horses.5,9,11 The antibacterial activity of
desacetylcephalothin is only one-half to one-
sixteenth that of cephalothin, the lowest value
corresponding to Bacillus subtilis ATCC 6633.15
Cephalothin plasma half-life elimination is
lower than 1 hour in most studied species.8,11
Parenteral first generation cephalosporins
are used, in human and veterinary medicine,
mainly for prophylaxis of surgical wound infec-
tions. Also, parenteral first generation
cephalosporins might be used to establish high
tissue levels rapidly before using an oral
cephalosporin.2 For surgical prophylaxis they
should be administered intravenously around
30 minutes prior to the first tissue incision (to
allow achieving therapeutic concentrations at
tissue level when the incision is performed)
only once. Administration can be repeated 90
minutes later in long lasting surgeries or when
significant blood loss occurs.16
The aim of this study was to characterize
the plasma pharmacokinetics and renal excre-
tion of cephalothin, as well as, to determine its




Experimental animals were nine, 1 to 1.5
years old, mixed-breed cats (4 female and 5
males) with an average weight of 4.36±0.98
kg. All cats were healthy as determined by clin-
ical examination, complete blood and serum
biochemical analysis and urinalysis.  Animals
were housed in the Faculty of Veterinary
Medicine, University of Buenos Aires facilities
and allowed to acclimatize for two months
before the experiment. Access to a high quality
commercial dry food (Purina ProPlan®,
Buenos Aires, Argentina) and water was ad
libitum. All animal procedures were approved
by the Institutional Animal Care and Use
Committee, School of Veterinary Science,
University of Buenos Aires, Argentina.
Dosage form
An aqueous 10% (cephalothin equivalent)
w/v solution of cephalothin sodium salt
(Keflin®, Ivax, Buenos Aires, Argentina) was
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administered intravenously at a dose rate of 30
mg/kg. The dose was diluted in 3 mL of saline
solution (NaCl 0.9%) before administration
and injected through the cephalic vein over a 2
minute period.
Experimental design
Prior starting the study, two catheters
(Jelco®, Smith Medical International Ltd.,
Milano, Italy) were placed into the cephalic
veins. One of them (24G), was for antibiotic
and fluid (NaCl 0.9%, 10 mL/kg/h) administra-
tion; and, the other (22G), for blood sample
withdrawal. 
Also, the urethra was catheterized to collect
all urine produced during the complete dura-
tion of the study (6 hours). 
Surgical procedures (ovariectomy or
orchidectomy) were performed according to
conventional standard techniques under gen-
eral parenteral anesthesia (midazolam 0.2
mg/kg, ketamine 10 mg/kg, xylazine 0.5
mg/kg). Cephalothin was administered intra-
venously 30 min prior first surgical incision.  
Blood sampling
Blood samples (0.7 mL) were collected with
a heparinized syringe at 0.08; 0.16; 0.33; 0.50;
0.75; 1; 1.50; 2; 3; 4; 6 hours after cephalothin
administration.
Samples were centrifuged at 1500 rpm, for
15 min, and then plasma was harvested and
stored at −20°C until analysis.
Urine sampling
Starting with an emptied urine bladder, all
urine produced after cephalothin administra-
tion was collected at one hour intervals. The
volume of each sample was recorded and an
aliquot was stored at −20°C.
Tissue sampling
Tissue samples (0.02-0.1 g) were taken at
0.5-1 h after cephalothin administration.
Selected tissues/organs were skin, subcuta-
neous, muscle, ovary, uterus, testicle and epi-
didymis. Samples were rinsed briefly with
saline solution and dried through gentle pres-
sure with sterile gauze for removing blood con-
tamination. Then, they were weighed and
stored at −20ºC.
Cephalothin was eluted from tissue samples
following a technique described by Bamberg et
al.17 Briefly, samples were cut into small pieces
and diluted with phosphate buffer pH 6 (in a
ratio 1:2 w/v) and incubated for 24 h at 4ºC,
applying agitation during the first 40 min of
incubation. Finally, they were centrifuged
(1500 rpm for 15 min) and the supernatant
harvested till assayed.
All collected samples (plasma, urine and tis-
sue) were assayed within two weeks after col-
lection.
Cephalothin determination
Cephalothin plasma, tissue and urine con-
centrations were determined by microbiologi-
cal assay  using Bacillus subtilis ATCC 6633 as
test microorganism.18 Standard curves were
prepared on normal cat plasma, phosphate
buffer pH 6 or normal cat urine, depending on
the sample matrix to be quantified.
Each sample was seeded in triplicate and
each standard dilution in quintuplicate. 
Limit of detection and quantification of the
method for the three assayed matrices was
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Table 1. Pharmacokinetic parameters (mean ± standard deviation) of cephalothin after
intravenous administration to cats at a dose rate of 30 mg/kg (n=9).
Pharmacokinetic parameter                                      Intravenous administration 
C1 (µg/mL)                                                                                                             254.68±98.43
C2 (µg/mL)                                                                                                              99.11±42.09
Cp(0) (µg/mL)                                                                                                       353.79±118.92
 l1 (h-1)                                                                                                                       8.03±5.63
 l2 (h-1)                                                                                                                    0.68±0.14
AUC(0-t) (µg.h/mL)                                                                                               187.23±35.67
AUC(0-∞) (µg.h/mL)                                                                                             189.69±36.66
K12 (h-1)                                                                                                                    3.89±3.53
K21 (h-1)                                                                                                                    2.96±2.17
T½(d) (h)                                                                                                                    0.14±0.10
Varea (L/kg)                                                                                                                0.23±0.05
V(d(ss)) (L/kg)                                                                                                           0.19±0.03
ClB (L/h.kg)                                                                                                               0.16±0.03
T½ (h)                                                                                                                        1.07±0.23
MRT (h)                                                                                                                    1.16±0.21
C1, C2 Y-axis intercept terms; Cp(0) plasma concentration at 0 time;  l1 distribution rate constant; l2 elimination rate constant; AUC(0-t) area
under the plasma concentration vs time curve from 0 to the last sampling time; AUC(0-∞) area under the plasma concentration vs time curve
from 0 to infinite; K12 rate constant for passage from central to peripheral compartment; K21 rate constant for passage from peripheral to cen-
tral compartment; Varea volume of distribution during the elimination phase; V(d(ss)) volume of distribution at steady state; t½(d) distribution
half life; ClB body clearance; t½ elimination half-life; MRT mean residence time.
Table 2. Cephalothin tissue concentrations (mean ± standard deviation) taken between
30-60 min after cephalothin administration and, tissue/plasma concentration ratio after
intravenous administration (30 mg/kg) to cats (n=9).
Tissue (n)           Tissue concentration (µg/g)           Tissue/plasma concentration ratio
Skin (9)                                            15.85±5.44                                                                0.17±0.05
Subcutaneous (4)                           6.37±3.62                                                                 0.06±0.03
Muscle (4)                                       6.46±1.85                                                                 0.06±0.02
Ovary (8)                                         18.24±4.38                                                                0.16±0.04
Uterus (4)                                       25.63±7.59                                                                0.21±0.05
Testicle (10)                                    3.73±0.60                                                                 0.04±0.01
Epididymis (10)                             12.79±2.01                                                                0.15±0.04
Table 3. Cephalothin urinary elimination (cumulative percentage of the administered
dose) after its intravenous administration to cats at a dose of 30 mg/kg (n=9). Data are
mean ± standard deviation.
                   Time after cephalothin                                     Cumulative percentage
                      administration (h)                                of the administered dose in urine 
                                                0-1                                                                                      34.16±6.57
                                                1-2                                                                                     51.65±12.91
                                                2-3                                                                                     59.89±16.08
                                                3-4                                                                                     63.77±17.19
                                                4-5                                                                                     65.75±17.85
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0.39 µg/mL and 0.78 µg/mL. The method was
linear between 0.39 and 200 µg/mL (r=0.9955).
Inter and intra-assay coefficients of variation
were less than 10%. Concentration results are
expressed as cephalothin concentrations.
However, since microbiological assay cannot
distinguish between cephalothin and its six-
teen times less active metabolite (acetyl-
cephalothin), the reported cephalothin con-




Individual cephalothin plasma concentra-
tion vs. time curves were analysed by non-lin-
ear least square regression analysis using a
computer software (Phoenix® WinNonlin®
6.3, 2005-2012, Certara, L.P., Princeton, USA). 
Initial estimates were determined using the
residual method and refitted by non linear
regression.19
The number of exponents needed for
cephalothin intravenous administration data
were determined by applying the Schwartz and
Akaike criterions,20,21 and the residual distri-
bution around the estimated concentrations.  
Most pharmacokinetic parameters were cal-
culated using classic equations associated
with compartmental analysis.19
Results
Adverse effects were not observed during or
following cephalothin intravenous administra-
tion in any of the cats. 
Cephalothin plasma disposition curves in all
the animals were best fitted to a biexponential
model (Figure 1) according to an open bicom-
partmental model:
C(t) = Y1 exp(-l1t) + Y2 exp(l2t)
where C(t) (mg/mL) represents cephalothin
plasma concentration at t time; Y1 and Y2
(mg/mL) are the concentrations extrapolated
to time 0 of the first and second phase of
cephalothin plasma disposition and l1 and l2
(per h) are the distribution and elimination
slopes, respectively. The average equation for
the model was:
Cp = 254.68 e-8.03 + 99.11 e-0.68t
Main pharmacokinetic parameters (mean ±
standard deviation) are reported in Table 1.
Cephalothlin showed a fast distribution,
reflected by the rate constant of the process
(l1 8.03±5.63 h-1) and its short half-life (T½(d)
0.14±0.10 h). The extent of distribution was
moderate (V(d(ss)) 0.19±0.03 L/kg).
Cephalothin was rapidly eliminated from
the body with a total body clearance (ClB) of
0.16±0.03 L/h.kg, an elimination half-life (T½)
of 1.07±0.23 h and a mean residence time
(MRT) of 1.16±0.21 h.
Cephalothin tissue concentrations and tis-
sue/plasma concentrations rates are shown in
Table 2. Tissue concentrations were always
lower than the corresponding plasma concen-
trations. The highest concentrations were
found in uterus, ovary and skin, while, the low-
est were found in testicle, subcutaneous and
muscle. 
Cephalothin was rapidly and extensively
eliminated in urine (66.49% of total the
administered dose in a 6 hour period). The
cumulative percentage excreted in urine
throughout the study is shown in Table 3.
Cephalothin urine concentrations were very
high at all sampling times, with a peak value of
5438.04±3545.27 µg/mL during the first hour
and, a minimum of 145.01±183.93 µg/mL dur-
ing the sixth hour.
Discussion
Cephalothin, as a representative member of
the parenteral first generation cephalosporins,
shares with the group the same clinical use
indications. That is the intravenous treatment
of soft tissue infections where a bacterial sus-
ceptibility test points a first generation
cephalosporin. Also, as same as cefazolin, it is
a good choice to prevent surgical site infec-
tions in clean-contaminated wounds. 
For these purposes and tending to a rational
usage, antibiotic pharmacokinetic features
and tissue concentrations should ideally be
characterized. The present study can bring
useful information since it describes
cephalothin plasma pharmacokinetics, tissue
concentrations, and urine elimination after its
intravenous administration to cats.
The study was conducted on anaesthetized
cats and, the authors are aware that under this
circumstances, the calculated pharmacokinet-
ic parameters could result altered. However,
we preferred choosing experimental condi-
tions those that simulated actual surgical set-
tings.
A weakness of the present study is that sam-
ples taken from tissues correspond to a unique
time point after cephalothin administration.
However, the sampling time was chosen taking
into consideration surgical timing when high-
est antibiotic concentrations in tissues are
required. 
Cephalothin concentrations in all the stud-
ied matrices were determined through the
microbiological assay.18 This method was
extensively used to determine cephalothin
concentrations in many studies.7-14,22,23
However, because the microbiological assay
does not discriminate between the active drug
(cephalothin) and its active metabolite
(acetylcephalothin), it is criticized for some
authors. Nevertheless, we have selected it
because of its sensibility, simplicity and good
correlation with HPLC determination.9
Plasma cephalothin disposition curves after
intravenous administration were best fitted by
an open bicompartmental model in all the cats.
This is in agreement with human and horses
pharmacokinetic studies.11,14
After cephalothin administration, initial
plasma extrapolated concentrations were very
high (Cp(0) 353.79 µg/mL), and declined rapidly
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Figure 1. Mean (±standard deviation) cephalothin plasma concentration-time profile (■)
and cumulative urine elimination (●) after intravenous administration to cats (n=9) at a
dose of 30 mg/kg. Minimum inhibitory concentration (MIC) values correspond to
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(as it is shown through the distribution and
elimination rate constants: l1, 8.03 h–1 and l2,
0.68 h–1). Cephalothin plasma concentrations
were still detectable (>1 µg/mL in 7/9 animals)
up to the last sampling time (6 h).
In general terms, plasma pharmacokinetic
profile of cephalothin in cats is the predicted
for a beta-lactam antibiotic, being similar to
that reported by other authors in other
species.5,9-11,13,14,23
Cephalothin in cats, as expected for a water-
soluble beta-lactam, seems to be distributed
exclusively into extracellular fluids, as reflect-
ed by the low V(d(ss)) (0.19 L/kg). However,
mean cephalothin tissue concentration after
≈1 h administration was above 1 µg/mL (MIC90
for Staphylococcus and Streptococcus
species).2 In a previous study performed on
mice, rats, rabbits and dogs, similar high
cephalothin tissue concentrations (in lung,
liver, spleen and kidney) were reported.7
Cephalothin concentrations found in tissues of
cats are high enough to prevent bacteria colo-
nization of soft tissues during common surgi-
cal procedures.
In the present study, differences were found
between tissues in the rate of cephalothin pen-
etration and, also in the tissue/plasma concen-
tration ratio. These differences are probably
due to anatomical and physiological particular-
ities of each sampled organ. Tissue/plasma
rates are in accordance to the magnitude of
cephalothin tissue concentration, corroborat-
ing that cephalothin penetrates into some tis-
sues (e.g. uterus) better than in others (e.g.
testicle). 
Estimated tissue/plasma ratios for all tis-
sues were always less than unity, confirming
that the distribution of cephalothin is restrict-
ed to the vascular and extracellular fluid.
In human beings, cephalothin is eliminated
mainly active (65%) through the kidneys by
tubular secretion and glomerular filtration
reaching very high urine concentrations.12 In
our study cephalothin (as total antibacterial
activity) was found in urine in quantities as
high as 5438.04 µg/mL and 145.01 µg/mL (dur-
ing the first and the last hour sampled, respec-
tively). It seems that cephalothin and its active
metabolite were eliminated faster in cats
(66.49% of the administered dose in 6 h) than
in men (66% in 24 h).23
To predict the theoretical efficacy of
cephalotin in the prophylaxis of surgical infec-
tions, plasma concentrations of cephalothin
could be compared to MIC values for pathogen-
ic bacteria that could colonize wounds. When
considering a MIC90 for Staphylococcus spp. of
1 µg/mL2 cephalothin plasma concentrations
remain above this value for ≈5.50 hours.
However, if MIC breakpoint for susceptible
bacteria (≤8 µg/mL)3 is considered, cephaloth-
in would be effective for only ≈2.5 hours. So,
depending on the expected contamination
source and the length of the surgery, it would
be advisable to repeat the administration 2
hours after the first dose. 
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